Alzheimer's disease pathology research company AlzPath and Quanterix expand a strategic licensing agreement to advance the next generation of Alzheimer's disease biomarkers research.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.